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Sport activity in patients with myocarditis and pericarditis 
 
Sportske aktivnosti kod bolesnika s miokarditisom i perikarditisom 
 




Mycarditis and pericarditis may be related with sudden cardiac death/cardiac arrest (SCD/CA) in athletes, 
not exclusively in those with reduced left ventricular systolic function, but also in subjects with normal cardiac 
function related to arrhythmias generated in the area of myocardial necrosis and scar. The diagnosis is based 
on a complete cardiac evaluation (12-lead ECG, echocardiography, cardiac magnetic resonance imaging, and 
endomyocardial biopsy).  
In this review, we outline the latest recommendations published by the Sport Cardiology Section of the 
European Association of Preventive Cardiology (EAPC) on sport activity with these patients. It offers 
recommendations for practicing cardiologists and sport physicians for safe participation in competitive sport 
at professional and amateur level. Participation in competitive sport should be considered on an individual 
basis, after the evaluation of the disease characteristics and risk determinants, and complete resolution of the 
inflammatory process.  





Miokarditis i perikarditis mogu biti povezani s iznenadnom smrću/kardijalnim arestom u sportaša, ne 
isključivo u onih s reduciranom sistoličkom funkcijom lijevog ventrikla, nego i kod osoba s normalnom 
srčanom funkcijom i aritmijama generiranima u području miokardijalne nekroze i ožiljka. Dijagnostika je 
bazirana na kompletnoj kardiološkoj obradi (elektrokardiogram, ehokardiografija, magnetska rezonancija 
srca, endomiokardijalna biopsija).  
U ovom preglednom članku donosimo najnovije preporuke Sekcije za sportsku kardiologiju pri 
Europskom društvu za preventivnu kardiologiju (engl. EAPC) o sportskoj aktivnosti kod navedenih bolesnika. 
Donosimo preporuke za kardiologe i sportske liječnike za sigurno sudjelovanje u kompetitivnom sportu na 
profesionalnoj i amaterskoj razini. Sudjelovanje u kompetitivnom sportu treba razmotriti na individualnoj 
bazi, nakon evaluacije karakteristika same bolesti i čimbenika rizika, i nakon kompletne rezolucije upalnoga 
procesa.  
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Myocarditis and pericarditis are usually infective 
etiology (ie. viral, tuberculosis), but also can be a 
consequence of autoimmune processes, and are related 
with sudden cardiac death/cardiac arrest (SCD/CA) in 
athletes. The diagnosis is based on complete cardiac 
evaluation (12-lead ECG, echocardiography, cardiac 
magnetic resonance imaging (CMRI)), including 
endomyocardial biopsy (EMB) at myocarditis of 
doubtful etiology (viral vs giant cell or sarcoidosis)             
for adequate treatment choice and prognosis 
improvement.1  
In this review article, we outline the latest 
recommendations published by the Sport Cardiology 
Section of the European Association of Preventive 
Cardiology (EAPC) on sport activity, which provides 
pragmatic advice for safe participation in competitive 




It is an inflammatory process of the myocardium, 
with histological evidence of myocyte degeneration 
and necrosis of non-ischaemic origin, associated with 
inflammatory infiltration.2,3 It could be a cause of 
SCD/CA with athletes in 2-8% of cases.4-6 Clinical 
presentation  may include respiratory symptoms, 
diarrhea, fatigue as well as arrhythmia, heart failure, or 




Routine evaluation should include the measurement 
of serum cardiac biomarkers.2,3 12-lead ECG may 
include ventricular and supraventricular arrhythmias, 
ST-segment alterations, T-wave inversion, various 
conduction abnormalities (LBBB, AV block) and low 
QRS amplitude (heart failure, pericardial effusion).7  
Echocardiographic changes may reveal a mild 
dilatation of LV cavity and thin myocardial walls (like 
in DCM). Other subjects may have normal LV cavity 
and increased LV wall thickness related to myocardial 
oedema.8 Other findings include LV sistolic 
dysfunction and pericardial effusion.9 CMRI has 
excellent sensitivity in detecting myocarditis and can 
identify hyperaemia, inflammation oedema, and/               
or focal scar.10,11 Detection of late gadolinium 
enhancement (LGE) is a strong independent predictor 
of events during follow-up.10-14 
Endomyocardial biopsy (EMB) is the gold-
standard for the diagnosis of myocarditis. Immune-
biochemical testing and polymerase chain reaction 
(PCR) analysis allows definitive diagnosis and 
identification of viral genome. EMB is not usually 
performed for clinical diagnosis, but it is crucial for 
differentiation between the viral and non-viral 
myocarditis (ie giant cell, sarcoidosis) and for  
adequate treatment choice as well as prognosis 




The major risk of SCD/CA is related to LV 
dysfunction and less with the severity of myocardial 
inflammation and serum concentrations of cardiac 
troponin.6, 17, 18 However, SCD/CA may occur despite 
normal LV function and is mostly related to 
tachyarrhythmias from the region of the remaining 
myocardial scar. Therefore, the interval between the 
initial assessment and retesting before resumption of 
sports will vary on individual basis depending on the 
severity of the initial illness and morphological 
sequelae. Thus, recommendations are as follows:  
• Athletes with diagnosis of myocarditis should be 
restricted from exercise programs for a period of 3–6 
months, according to the clinical severity and duration 
of the illness, LV function at onset, and extent of 
inflammation on the CMRI. This time period is 
considered appropriate to ensure the clinical and 
biological resolution of the disease (Class IIb/Level 
C);3,17-21 
• Individuals with previous myocarditis have an 
increased risk for recurrence and silent clinical 
progression of the disease. Therefore, athletes with 
previous myocarditis should undergo a periodical re-
assessment, particularly within the first 2 years (Class 
IIa/ Level C);   
• It is reasonable for athletes to resume training and 
competition after myocarditis, if all of the following 
criteria are met: LV systolic function has returned to 
the normal range, serum biomarkers of myocardial 
injury have normalized, and clinically relevant 
arrhythmias, such as frequent or complex repetitive 
forms of ventricular or supraventricular arrhythmias 
are absent on 24-h ECG monitoring and exercise test 
(Class IIa/ Level C); and  
• The clinical significance of persistent LGE in            
an asymptomatic athlete with clinically healed 
myocarditis is unknown. However, a myocardial scar 
is a potential source of ventricular tachyarrhythmias.12-14 
At present, it seems reasonable for these athletes to 
resume training and participate in competitive sport if 
LV function is preserved and in the absence of frequent 
or complex repetitive forms of ventricular or supra-
ventricular arrhythmias during maximal exercise and 
on 24-h ECG monitoring (including session of 
training/competition). Asymptomatic athletes with 
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LGE, however, should remain under annual clinical 




Pericarditis is defined as an inflammatory process 
of the pericardium, with potential involvement of  the 
sub-epicardial layers of the myocardium.3,22 It is 
usually caused by viruses, while in developing 
countries the most frequent cause is tuberculosis.22,23 
Clinical presentation may include chest pain, fatigue 
and dyspnoea, usually preceded with respiratory            
and gastrointestinal symptoms. Pericarditis and 
myocarditis may coexist (20–30%), with elevation of 
serum cardiac troponins and myocardial edema on 
CMR. Such subjects have an increased risk for 




Increased serum cardiac biomarkers may be related 
to myocardial involvement.23 The 12-lead ECG may 
include widespread ST-segment elevation, or PR 
interval depression in the acute phase. Echo-
cardiographic changes may include pericardial 
effusion at the onset of the disease, while pericarditis 
with increased biomarkers for cardiac damage should 





Individuals with pericarditis usually have an 
excellent prognosis with complete resolution of the 
pathological process.3,22,23 However, patients with 
idiopathic acute pericarditis and certain features at 
presentation (temperature >38°C), subacute course, 
large pericardial effusion, and resistance to non-
steroidal anti-inflammatory drugs comprise a subset of 
patients with a more guarded prognosis and a greater 
risk for recurrence and progressing to pericardial 
constriction.3,18,23 Thus, recommendations are as 
follows:  
• Athletes with pericarditis should not participate in 
competitive sports during the acute phase. Athletes can 
return to sport activity only after a complete resolution 
of the active disease. The time period of 3 months is 
considered appropriate to ensure a complete clinical 
and biological resolution of the disease, but a shorter 
period (at least 1 month) may be considered in selected 
cases with only a mild clinical picture and prompt 
resolution. (Class III, Level C);  
• It is reasonable to return to play if the serum 
biomarkers have normalized, LV function is normal 
and there are no resting, or exercise-induced frequent/ 
complex ventricular arrhythmias detectable on 24-h 
ECG monitoring or exercise ECG (Class IIa, Level C); 
• Athletes with concomitant myocardial 
involvement should be treated in accordance with the 
recommendations for myocarditis (Class IIa, Level C); 
and   
• Asymptomatic athletes with small pericardial 
effusion, detected incidentally by imaging testing, but 
without clinical, biochemical and CMR evidence of 
myocardial inflammation, should not be considered as 
affected by myopericarditis and should not be 
restricted from sport participation. A periodical 




The diagnosis of myocarditis and pericarditis is 
based on complete cardiac evaluation (12-lead ECG, 
echocardiography, CMRI), including EMB in patients 
with myocarditis of doubtful etiology. Both entities 
may be the cause of SCD/CA in athletes, not 
exclusively in those with reduced LV systolic function, 
but also in subjects with normal cardiac function 
related to arrhythmias generated in the area of 
myocardial necrosis and scar. Participation in 
competitive sport should be considered on an 
individual basis, after the evaluation of the disease 
characteristics and risk determinants, and complete 
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